I now have all the content needed for a comprehensive answer. Let me compile the full response.
Biosynthesis of Cholesterol
Cholesterol is a 27-carbon sterol synthesized from acetyl-CoA through a multi-stage pathway. Virtually all nucleated cells can make cholesterol, but the liver, intestine, adrenal cortex, and reproductive tissues (ovaries, testes, placenta) are the largest contributors. About 700 mg/day is synthesized endogenously; the rest comes from diet. The pathway occurs in the cytosol and smooth endoplasmic reticulum (SER), and requires NADPH as the reducing agent and ATP as energy. All 27 carbons come from acetyl-CoA.
Overview: Five Major Stages
| Stage | Key Input | Key Output |
|---|
| 1 | Acetyl-CoA | Mevalonate |
| 2 | Mevalonate | Isopentenyl pyrophosphate (IPP) |
| 3 | IPP (x6) | Squalene |
| 4 | Squalene | Lanosterol |
| 5 | Lanosterol | Cholesterol |
Stage 1: Acetyl-CoA → Mevalonate
This is the most regulated stage, containing the rate-limiting step.
Step 1a - HMG-CoA synthesis (cytosol):
- Two molecules of acetyl-CoA condense via cytosolic thiolase to form acetoacetyl-CoA (4C)
- A third acetyl-CoA is added by HMG-CoA synthase (cytosolic isoform) to produce 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) (6C)
Fig. 18.3 - Lippincott's Biochemistry: Synthesis of HMG-CoA
Note: There are two HMG-CoA synthase isoenzymes - the cytosolic one feeds cholesterol synthesis; the mitochondrial one feeds ketogenesis. The two pathways are distinct compartmentally.
Step 1b - Mevalonate synthesis (SER):
- HMG-CoA is reduced to mevalonate (6C) by HMG-CoA reductase (HMGCR)
- Reaction: HMG-CoA + 2 NADPH → Mevalonate + CoA
- This is irreversible, uses 2 NADPH, and is the rate-limiting, regulated step of the entire pathway
Harper's Biochemistry Fig. 26-1: HMG-CoA reductase is the key regulatory enzyme
Stage 2: Mevalonate → Isopentenyl Pyrophosphate (IPP)
- Mevalonate undergoes two sequential phosphorylations by ATP kinases → 5-pyrophosphomevalonate
- Decarboxylation (requires ATP) produces isopentenyl pyrophosphate (IPP), the fundamental 5-carbon isoprene unit
- IPP is isomerized to dimethylallyl pyrophosphate (DMAPP / DPP) by IPP isomerase
IPP is the precursor of the entire isoprenoid family - cholesterol is a sterol isoprenoid; non-sterol isoprenoids produced here include dolichol, ubiquinone (CoQ10), and prenyl groups on proteins like Ras.
Stage 3: IPP → Squalene (30C)
Sequential head-to-tail condensations:
- IPP + DMAPP → geranyl pyrophosphate (GPP, 10C)
- GPP + IPP → farnesyl pyrophosphate (FPP, 15C)
- Two FPP molecules combine tail-to-tail (NADPH required) → squalene (30C)
Squalene synthesis requires 18 ATP total (3 ATP per mevalonate unit × 6 isoprene units).
FPP is also used in protein prenylation (farnesylation of Ras oncoproteins) - a key reason statins may have anti-tumor effects.
Stage 4: Squalene → Lanosterol (first sterol ring)
- Squalene epoxidase (SER) uses O₂ and NADPH to form squalene-2,3-epoxide
- The epoxide undergoes cyclization catalyzed by oxidosqualene cyclase (lanosterol cyclase), forming the tetracyclic steroid ring structure: lanosterol (30C)
This step generates the characteristic steroid ring (A-B-C-D ring system) in one concerted reaction.
Stage 5: Lanosterol → Cholesterol
A series of ~19 enzymatic steps in the SER convert lanosterol (30C) to cholesterol (27C):
- Three methyl groups are removed (losing 3C as CO₂)
- The side chain double bond is reduced
- The ring double bond migrates from C-8 to C-5
- Final step: 7-dehydrocholesterol reductase (DHCR7) reduces the Δ7 double bond to yield cholesterol
Smith-Lemli-Opitz syndrome is caused by a partial deficiency of DHCR7, leading to accumulation of 7-dehydrocholesterol, low cholesterol levels, and multiple developmental abnormalities.
Regulation of Cholesterol Synthesis
The principal regulatory point is HMG-CoA reductase. Four mechanisms operate:
Lippincott's Fig. 18.7 - Regulation of HMG-CoA reductase
1. Transcriptional Regulation (SREBP-2 Pathway)
- When intracellular cholesterol is low, SCAP (SREBP cleavage-activating protein) escorts SREBP-2 from the ER to the Golgi
- Proteolytic cleavage releases the active transcription factor, which moves to the nucleus and binds SRE (sterol regulatory element)
- This upregulates transcription of HMG-CoA reductase and the LDL receptor
- When cholesterol is high, INSIG proteins retain the SCAP-SREBP complex in the ER - SREBP-2 is not released, transcription stops
2. Accelerated Enzyme Degradation
- When ER sterol levels are high, the reductase binds INSIG proteins, is ubiquitinated, and undergoes proteasomal degradation
3. Phosphorylation/Dephosphorylation
- AMP-activated protein kinase (AMPK) phosphorylates and inactivates HMG-CoA reductase
- Phosphoprotein phosphatase dephosphorylates and activates it
- When AMP (low energy) is high, AMPK is activated → reductase is inactivated → cholesterol synthesis decreases (similar to fatty acid synthesis control)
4. Hormonal Regulation
- Insulin → promotes dephosphorylation → activates reductase (fed state, anabolism)
- Glucagon / Epinephrine → promotes phosphorylation → inactivates reductase (fasted/stress state)
Clinical Relevance: Statins
Statins (atorvastatin, simvastatin, rosuvastatin, etc.) are structural analogs of HMG-CoA that act as reversible competitive inhibitors of HMG-CoA reductase - the rate-limiting enzyme. By lowering intracellular cholesterol, they trigger SREBP-2 activation, which also upregulates LDL receptors, increasing LDL clearance from plasma.
Key side effects include myopathy/rhabdomyolysis, partly because the mevalonate pathway also supplies heme A and ubiquinone (CoQ10), both needed for mitochondrial oxidative phosphorylation. A genetic polymorphism in the transporter OATP1B1 (SLCO1B1 521 T>C) is a biomarker for simvastatin-induced myopathy.
Summary Pathway
Acetyl-CoA (x3)
↓ [Thiolase + HMG-CoA synthase]
HMG-CoA (6C)
↓ [HMG-CoA reductase] ← RATE-LIMITING STEP (statin target)
Mevalonate (6C)
↓ [Kinases + decarboxylase, 3 ATP]
IPP / DMAPP (5C isoprene units)
↓ [Prenyltransferases]
Farnesyl-PP (15C) × 2
↓ [Squalene synthase, NADPH]
Squalene (30C)
↓ [Squalene epoxidase + Lanosterol cyclase, O₂ + NADPH]
Lanosterol (30C)
↓ [~19 SER reactions, NADPH]
Cholesterol (27C)
Sources:
- Biochemistry, 8th ed. Lippincott Illustrated Reviews, Chapter 18 (Cholesterol Synthesis, pp. 617-627)
- Harper's Illustrated Biochemistry, 32nd Ed., Chapter 26 (Cholesterol Biosynthesis)